Real-world experience of leadless left ventricular endocardial cardiac resynchronization therapy: A multicenter international registry of the WiSE-CRT pacing system
Benjamin J Sieniewicz, Timothy R Betts, Simon James, Andrew Turley, Christian Butter, Martin Seifert, Lucas V A Boersma, Sam Riahi, Petr Neuzil, Mauro Biffi, Igor Diemberger, Pasquale Vergara, Martin Arnold, David T Keane, Pascal Defaye, Jean-Claude Deharo, Anthony Chow, Richard Schilling, Jonathan Behar, Christopher A Rinaldi, Benjamin J Sieniewicz, Timothy R Betts, Simon James, Andrew Turley, Christian Butter, Martin Seifert, Lucas V A Boersma, Sam Riahi, Petr Neuzil, Mauro Biffi, Igor Diemberger, Pasquale Vergara, Martin Arnold, David T Keane, Pascal Defaye, Jean-Claude Deharo, Anthony Chow, Richard Schilling, Jonathan Behar, Christopher A Rinaldi
Abstract
Background: Biventricular endocardial pacing (BiV ENDO) is a therapy for heart failure patients who cannot receive transvenous epicardial cardiac resynchronization therapy (CRT) or have not responded adequately to CRT. BiV ENDO CRT can be delivered by a new wireless LV ENDO pacing system (WiSE-CRT system; EBR Systems, Sunnyvale, CA), without the requirement for lifelong anticoagulation.
Objective: The purpose of this study was to assess the safety and efficacy of the WiSE-CRT system during real-world clinical use in an international registry.
Methods: Data were prospectively collected from 14 centers implanting the WiSE-CRT system as part of the WiCS-LV Post Market Surveillance Registry. (ClinicalTrials.gov Identifier: NCT02610673).
Results: Ninety patients from 14 European centers underwent implantation with the WiSE-CRT system. Patients were predominantly male, age 68.2 ± 10.5 years, left ventricular ejection fraction 30.6% ± 8.9%, mean QRS duration 180.7 ± 27.0 ms, and 40% with ischemic etiology. Successful implantation and delivery of BiV ENDO pacing was achieved in 94.4% of patients. Acute (<24 hours), 1- to 30-day, and 1- to 6-month complications rates were 4.4%, 18.8%, and 6.7%, respectively. Five deaths (5.6%) occurred within 6 months (3 procedure related). Seventy percent of patients had improvement in heart failure symptoms.
Conclusion: BiV ENDO pacing with the WiSE-CRT system seems to be technically feasible, with a high success rate. Three procedural deaths occurred during the study. Procedural complications mandate adequate operator training and implantation at centers with immediately available cardiothoracic and vascular surgical support.
Keywords: Cardiac resynchronization therapy; Endocardial pacing; Heart failure; Leadless pacing; Nonresponder.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Figures
References
- Petersen S., Rayner M., Wolstenholme J. British Heart Foundation; London: 2002. Coronary Heart Disease Statistics: Heart Failure Supplement.
- Neeland I.J., Kontos M.C., de Lemos J.A. Evolving considerations in the management of patients with left bundle branch block and suspected myocardial infarction. J Am Coll Cardiol. 2012;60:96–105.
- Nelson G.S., Berger R.D., Fetics B.J. Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block. Circulation. 2000;102:3053–3059.
- Cleland J.G.F., Daubert J.C., Erdmann E. Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–1549.
- European Society of Cardiology (ESC) European Heart Rhythm Association (EHRA), Brignole M, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association. Europace. 2013;15:1070–1118.
- Yu C.-M., Bleeker G.B., Fung J.W.-H. Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. Circulation. 2005;112:1580–1586.
- Gamble J.H.P., Herring N., Ginks M., Rajappan K., Bashir Y., Betts T.R. Procedural success of left ventricular lead placement for cardiac resynchronization therapy. JACC Clin Electrophysiol. 2016;2:69–77.
- Abu-El-Haija B., Bhave P.D., Campbell D.N. Venous stenosis after transvenous lead placement: a study of outcomes and risk factors in 212 consecutive patients. J Am Heart Assoc. 2015;4
- Morgan J.M., Biffi M., Gellér L. ALternate Site Cardiac ResYNChronization (ALSYNC): a prospective and multicentre study of left ventricular endocardial pacing for cardiac resynchronization therapy. Eur Heart J. 2016;37:2118–2127.
- Auricchio A., Delnoy P.P., Regoli F., Seifert M., Markou T., Butter C. First-in-man implantation of leadless ultrasound-based cardiac stimulation pacing system: novel endocardial left ventricular resynchronization therapy in heart failure patients. Europace. 2013;15:1191–1197.
- Auricchio A., Delnoy P.P.P.-P., Butter C. Feasibility, safety, and short-term outcome of leadless ultrasound-based endocardial left ventricular resynchronization in heart failure patients: Results of the Wireless Stimulation Endocardially for CRT (WiSE-CRT) study. Europace. 2014;16:681–688.
- Reddy V.Y., Miller M.A., Neuzil P. Cardiac resynchronization therapy with wireless left ventricular endocardial pacing: the SELECT-LV study. J Am Coll Cardiol. 2017;69:2119–2129.
- Sieniewicz B.J., Behar J.M., Gould J. Guidance for optimal site selection of a leadless left ventricular endocardial electrode improves acute hemodynamic response and chronic remodeling. JACC Clin Electrophysiol. 2018;4:860–868.
- Sieniewicz B.J., Gould J., Rimington H.M., Ioannou N., Rinaldi C.A. Transseptal delivery of a leadless left ventricular endocardial pacing electrode. JACC Clin Electrophysiol. 2017;3:1333–1335.
- Nasu K., Tsuchikane E., Sumitsuji S., PARADISE Investigators Clinical effectiveness of the Prostar XL suture-mediated percutaneous vascular closure device following PCI: results of the Perclose AcceleRated Ambulation and DISchargE (PARADISE) Trial. J Invasive Cardiol. 2003;15:251–256.
- James S., Rinaldi C.A., Turley A.J. First-in-man implantation of a leadless endocardial left ventricular pacing system (WiSE-CRT) utilising a trans-septal approach. EP Europace. 2018;20(Suppl 4):iv16.
- Schmidt B., Betts T.R., Sievert H. Incidence of pericardial effusion after left atrial appendage closure: the impact of underlying heart rhythm—data from the EWOLUTION study. J Cardiovasc Electrophysiol. 2018;29:973–978.
Source: PubMed